Emerging in the arena of weight management treatment, retatrutide represents a distinct method. Unlike many current medications, retatrutide operates as a double agonist, concurrently targeting both GLP-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. The simultaneous stimulation promotes various helpful effects,